<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:52e1360b-92ec-42ad-a624-757096e53103,g:1d7aeb9b-e482-4512-b506-df340fee02f9,d:df058c9608534f2d8c8ed15f09518758--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>athx-20220114</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF80L2ZyYWc6MzQyNmVhYWE1YTkzNDcwNGI4ZDgyOTA0YTNmNTM2NTkvdGFibGU6YjQ4ZWEzMGZlNTliNDQzYzllODEyMTQxYzYyMzI4NDYvdGFibGVyYW5nZTpiNDhlYTMwZmU1OWI0NDNjOWU4MTIxNDFjNjIzMjg0Nl8yLTEtMS0xLTE4ODI3_27ce675e-3361-49df-82be-d75f807421b8">false</ix:nonNumeric><ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF80L2ZyYWc6MzQyNmVhYWE1YTkzNDcwNGI4ZDgyOTA0YTNmNTM2NTkvdGFibGU6YjQ4ZWEzMGZlNTliNDQzYzllODEyMTQxYzYyMzI4NDYvdGFibGVyYW5nZTpiNDhlYTMwZmU1OWI0NDNjOWU4MTIxNDFjNjIzMjg0Nl8zLTEtMS0xLTE4ODI3_ba64b5bb-1a84-4998-8d6c-c8cdbb1ab511">ATHERSYS, INC / NEW</ix:nonNumeric><ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF80L2ZyYWc6MzQyNmVhYWE1YTkzNDcwNGI4ZDgyOTA0YTNmNTM2NTkvdGFibGU6YjQ4ZWEzMGZlNTliNDQzYzllODEyMTQxYzYyMzI4NDYvdGFibGVyYW5nZTpiNDhlYTMwZmU1OWI0NDNjOWU4MTIxNDFjNjIzMjg0Nl80LTEtMS0xLTE4ODI3_25c4293e-dcf3-4de2-97c5-cdd4776662f2">0001368148</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="athx-20220114.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i204d1f495951467bad3a471e24b2f135_D20220114-20220114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368148</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-14</xbrli:startDate><xbrli:endDate>2022-01-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="idf058c9608534f2d8c8ed15f09518758_1"></div><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:27.631%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF8xL2ZyYWc6OTdhYTRhNjE4YjcxNDg3MmE1OGI1MThkZGE5NjU4OGIvdGV4dHJlZ2lvbjo5N2FhNGE2MThiNzE0ODcyYTU4YjUxOGRkYTk2NTg4Yl8xODY5_dc19fd52-a607-4ab7-981e-d1424a44c7d3">8-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:27.631%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">of the Securities Exchange Act of 1934</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Date of report (Date of earliest event reported): <ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF8xL2ZyYWc6OTdhYTRhNjE4YjcxNDg3MmE1OGI1MThkZGE5NjU4OGIvdGV4dHJlZ2lvbjo5N2FhNGE2MThiNzE0ODcyYTU4YjUxOGRkYTk2NTg4Yl8yMzI_6f771a86-b36c-439d-88fa-766f1cfadc3c">January 14, 2022</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:27.631%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%">Athersys, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Charter)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:27.631%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.75pt"><tr><td style="width:1.0pt"></td><td style="width:159.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:159.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:13.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:159.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF8xL2ZyYWc6OTdhYTRhNjE4YjcxNDg3MmE1OGI1MThkZGE5NjU4OGIvdGFibGU6ZDVmOGQxMDkwN2FiNGZjNzlmODA5OTc0NzUwNjEyYmUvdGFibGVyYW5nZTpkNWY4ZDEwOTA3YWI0ZmM3OWY4MDk5NzQ3NTA2MTJiZV8wLTAtMS0xLTE4ODI3_1c484e81-1ce0-4c92-b1de-b28fec3476b2">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF8xL2ZyYWc6OTdhYTRhNjE4YjcxNDg3MmE1OGI1MThkZGE5NjU4OGIvdGFibGU6ZDVmOGQxMDkwN2FiNGZjNzlmODA5OTc0NzUwNjEyYmUvdGFibGVyYW5nZTpkNWY4ZDEwOTA3YWI0ZmM3OWY4MDk5NzQ3NTA2MTJiZV8wLTItMS0xLTE4ODI3_28810ce6-7d76-4d6e-8667-2ef97de66109">001-33876</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF8xL2ZyYWc6OTdhYTRhNjE4YjcxNDg3MmE1OGI1MThkZGE5NjU4OGIvdGFibGU6ZDVmOGQxMDkwN2FiNGZjNzlmODA5OTc0NzUwNjEyYmUvdGFibGVyYW5nZTpkNWY4ZDEwOTA3YWI0ZmM3OWY4MDk5NzQ3NTA2MTJiZV8wLTQtMS0xLTE4ODI3_09c0fcfe-e353-478b-8234-542815ee3ead">20-4864095</ix:nonNumeric></span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or Other Jurisdiction<br/>of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Commission<br/>File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:456.00pt"><tr><td style="width:1.0pt"></td><td style="width:102.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:49.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:25.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:88.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:181.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF8xL2ZyYWc6OTdhYTRhNjE4YjcxNDg3MmE1OGI1MThkZGE5NjU4OGIvdGFibGU6MzcxM2UwY2M4MDhmNDk1ZmI0M2ZkZDJiMzYyNDlmOTQvdGFibGVyYW5nZTozNzEzZTBjYzgwOGY0OTVmYjQzZmRkMmIzNjI0OWY5NF8wLTAtMS0xLTE4ODI3_b4db06d9-75f4-45c2-9492-90c828d29a62">3201 Carnegie Avenue,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF8xL2ZyYWc6OTdhYTRhNjE4YjcxNDg3MmE1OGI1MThkZGE5NjU4OGIvdGFibGU6MzcxM2UwY2M4MDhmNDk1ZmI0M2ZkZDJiMzYyNDlmOTQvdGFibGVyYW5nZTozNzEzZTBjYzgwOGY0OTVmYjQzZmRkMmIzNjI0OWY5NF8wLTEtMS0xLTE4ODI3_40f0c036-abe8-4720-ba42-e7b614162a16">Cleveland,</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF8xL2ZyYWc6OTdhYTRhNjE4YjcxNDg3MmE1OGI1MThkZGE5NjU4OGIvdGFibGU6MzcxM2UwY2M4MDhmNDk1ZmI0M2ZkZDJiMzYyNDlmOTQvdGFibGVyYW5nZTozNzEzZTBjYzgwOGY0OTVmYjQzZmRkMmIzNjI0OWY5NF8wLTItMS0xLTE4ODI3_9fcca017-d268-493e-9102-7b218d15ab86">Ohio</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF8xL2ZyYWc6OTdhYTRhNjE4YjcxNDg3MmE1OGI1MThkZGE5NjU4OGIvdGFibGU6MzcxM2UwY2M4MDhmNDk1ZmI0M2ZkZDJiMzYyNDlmOTQvdGFibGVyYW5nZTozNzEzZTBjYzgwOGY0OTVmYjQzZmRkMmIzNjI0OWY5NF8wLTQtMS0xLTE4ODI3_ab9a3a64-1750-4c8b-a7ed-ca6bb7aad7a9">44115-2634</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF8xL2ZyYWc6OTdhYTRhNjE4YjcxNDg3MmE1OGI1MThkZGE5NjU4OGIvdGV4dHJlZ2lvbjo5N2FhNGE2MThiNzE0ODcyYTU4YjUxOGRkYTk2NTg4Yl8zNzI_03110973-ca49-4d37-a748-a1365a09088b">216</ix:nonNumeric>) <ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF8xL2ZyYWc6OTdhYTRhNjE4YjcxNDg3MmE1OGI1MThkZGE5NjU4OGIvdGV4dHJlZ2lvbjo5N2FhNGE2MThiNzE0ODcyYTU4YjUxOGRkYTk2NTg4Yl8xODcx_3fe3c74c-a12e-4299-8588-f8645eb7c68a">431-9900</ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:27.631%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF8xL2ZyYWc6OTdhYTRhNjE4YjcxNDg3MmE1OGI1MThkZGE5NjU4OGIvdGFibGU6YjAxY2VkNDU2Zjk3NDY3YmEwOTM2Mjg2Y2E0MDhhY2MvdGFibGVyYW5nZTpiMDFjZWQ0NTZmOTc0NjdiYTA5MzYyODZjYTQwOGFjY18wLTAtMS0xLTE4ODI3_ecde0f71-d765-4eb1-a333-c37a4998ade9">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF8xL2ZyYWc6OTdhYTRhNjE4YjcxNDg3MmE1OGI1MThkZGE5NjU4OGIvdGFibGU6YTc2NTY0OTdmNjgyNDVlMWFjYTY4ZjZlYjliNzg1NDEvdGFibGVyYW5nZTphNzY1NjQ5N2Y2ODI0NWUxYWNhNjhmNmViOWI3ODU0MV8wLTAtMS0xLTE4ODI3_2a18ef13-d226-47c8-90d9-6fa8268ca40a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF8xL2ZyYWc6OTdhYTRhNjE4YjcxNDg3MmE1OGI1MThkZGE5NjU4OGIvdGFibGU6YTQ5NWFlOGJjN2YzNDRmNzhiZWRhNDJjZWJmMzVlNjcvdGFibGVyYW5nZTphNDk1YWU4YmM3ZjM0NGY3OGJlZGE0MmNlYmYzNWU2N18wLTAtMS0xLTE4ODI3_751107bc-880e-4b06-b68d-3a43c6eff301">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr></table></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF8xL2ZyYWc6OTdhYTRhNjE4YjcxNDg3MmE1OGI1MThkZGE5NjU4OGIvdGFibGU6MDVmZGM5OTExOTNjNDY1Y2JlMjJhNGRiZWY3N2Q3ODYvdGFibGVyYW5nZTowNWZkYzk5MTE5M2M0NjVjYmUyMmE0ZGJlZjc3ZDc4Nl8wLTAtMS0xLTE4ODI3_cc4418a6-3e29-4cd5-9935-6ac03e041417">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.906%"><tr><td style="width:1.0%"></td><td style="width:33.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF8xL2ZyYWc6OTdhYTRhNjE4YjcxNDg3MmE1OGI1MThkZGE5NjU4OGIvdGFibGU6ZDEyYjkxNzI0N2IxNDZjNDhkNWU3ZWE2YTIxMGYwNzYvdGFibGVyYW5nZTpkMTJiOTE3MjQ3YjE0NmM0OGQ1ZTdlYTZhMjEwZjA3Nl8xLTAtMS0xLTE4ODI3_37b6a65e-892d-48ea-a193-0010850c5fd5">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF8xL2ZyYWc6OTdhYTRhNjE4YjcxNDg3MmE1OGI1MThkZGE5NjU4OGIvdGFibGU6ZDEyYjkxNzI0N2IxNDZjNDhkNWU3ZWE2YTIxMGYwNzYvdGFibGVyYW5nZTpkMTJiOTE3MjQ3YjE0NmM0OGQ1ZTdlYTZhMjEwZjA3Nl8xLTEtMS0xLTE4ODI3_ef08396e-ca0d-429c-9341-1fb8fbe914d0">ATHX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF8xL2ZyYWc6OTdhYTRhNjE4YjcxNDg3MmE1OGI1MThkZGE5NjU4OGIvdGFibGU6ZDEyYjkxNzI0N2IxNDZjNDhkNWU3ZWE2YTIxMGYwNzYvdGFibGVyYW5nZTpkMTJiOTE3MjQ3YjE0NmM0OGQ1ZTdlYTZhMjEwZjA3Nl8xLTItMS0xLTE4ODI3_4d98051e-c63b-4d6c-8082-a4df97c4d90f">The NASDAQ Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company&#160;&#160;<ix:nonNumeric contextRef="i204d1f495951467bad3a471e24b2f135_D20220114-20220114" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmRmMDU4Yzk2MDg1MzRmMmQ4YzhlZDE1ZjA5NTE4NzU4L3NlYzpkZjA1OGM5NjA4NTM0ZjJkOGM4ZWQxNWYwOTUxODc1OF8xL2ZyYWc6OTdhYTRhNjE4YjcxNDg3MmE1OGI1MThkZGE5NjU4OGIvdGV4dHJlZ2lvbjo5N2FhNGE2MThiNzE0ODcyYTU4YjUxOGRkYTk2NTg4Yl8xODcy_4bc6b51c-2ec8-4148-bcf5-05edd0dc0786">&#9744;</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:1pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.02&#160;&#160;&#160;&#160;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/></span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 20, 2022, Athersys, Inc. (the "Company", "we", "us", or "our") announced that the Board of Directors of the Company (the &#8220;Board&#8221;) appointed Daniel A. Camardo to the Board and also named Mr. Camardo as the Company&#8217;s Chief Executive Officer, each effective as of February 14, 2022. William O. Lehmann, the Company's Interim Chief Executive Officer, will continue to serve as the Company's President and Chief Operating Officer. </span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Camardo, age 53, currently serves as the President, U.S., and the Executive Vice President of Horizon Therapeutics plc, a global biotechnology company, at the Rare Disease and Inflammation Business Unit and previously served as Group Vice President </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from September 2015 to August 2020. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before joining Horizon Therapeutics, Mr. Camardo was Vice President of Sales and Operations at Clarus Therapeutics, a start-up company focused on men's health, from July 2014 to September 2015. Prior to joining Clarus Therapeutics, Mr. Camardo served from 2003 to 2014 at Astellas Pharma US, an affiliate of Astellas Pharma Inc., a Japanese global pharmaceutical research company, in various roles, including Senior Director, U.S. Commercial Operations and Senior Director, Market Intelligence and Analytics.</span></div><div style="margin-top:8pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with Mr. Camardo&#8217;s appointment as Chief Executive Officer, we have entered into an offer letter agreement with Mr. Camardo (the &#8220;Offer Letter&#8221;), the key compensation terms of which are expected to be memorialized in an employment agreement with Mr. Camardo (an &#8220;Employment Agreement&#8221;). The Offer Letter includes the following material terms:</span></div><div><span><br/></span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mr. Camardo&#8217;s annual base salary rate during the term of his employment will be $600,000, subject to potential increases from time to time at the discretion of the Board or the Compensation Committee of the Board (the &#8220;Committee&#8221;).</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A cash signing bonus of $250,000, to be paid within 30 days of the date Mr. Camardo commences employment with the Company (the &#8220;Commencement Date&#8221;). In the event that Mr. Camardo voluntarily terminates his employment within twelve months of the Commencement Date, he will be required to repay the full amount of the signing bonus.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">As an inducement to Mr. Camardo&#8217;s acceptance of employment with the Company, the Company has determined to grant to Mr. Camardo an initial equity award that is intended to be an inducement award under Rule 5635(c)(4) of the Nasdaq Stock Market Listing Rules (the &#8220;Inducement Award&#8221;). The Inducement Award will be a stock option award to purchase 10,000,000 shares of the Company&#8217;s common stock at a per share exercise price equal to the closing price of a share of the Company&#8217;s common stock on the grant date. With regard to 4,000,000 shares, vesting of the Inducement Award will generally occur over a four-year period, with 25% of such portion of the award generally vesting on the first anniversary of the grant date and the remainder generally vesting monthly in substantially equal installments over the remaining 36 months. With regard to 6,000,000 shares, vesting of the Inducement Award will generally occur upon achievement of certain Company milestones, including FDA manufacturing process and marketing approvals, cumulative product sales, and business development and fundraising activities, as and when reasonably evaluated and determined by the Board in its sole discretion. The Inducement Award will generally have a 10-year term.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mr. Camardo will be eligible to participate, during his employment, in the Company&#8217;s annual cash incentive compensation program (the &#8220;Annual Incentive Program&#8221;) on terms substantially similar to those that apply to other executive officers of the Company, with a target annual cash incentive opportunity equal to 60% of Mr. Camardo&#8217;s annual base salary (and no guaranteed minimum payment), subject to Company performance as designed annually for the Annual Incentive Program by the Board or the Committee.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Beginning in 2022, Mr. Camardo will be eligible to participate, during his employment, in the Company&#8217;s annual stock-based award program on terms substantially similar to those that apply to other executive officers of the Company. The terms of such awards will be determined annually at the discretion of the Board or the Committee.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">While employed by the Company, Mr. Camardo will be eligible to participate in the Company&#8217;s employee benefit plans (including certain retirement and health and welfare benefit plans) on terms substantially similar to those that apply for other executive officers of the Company from time to time. Mr. Camardo will also be entitled to 20 days of paid vacation per year of full-time employment with the Company.</span></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mr. Camardo will be entitled to receive certain severance benefits under the terms of the Employment Agreement.  </span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:8pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Offer Letter provides that Mr. Camardo&#8217;s employment as Chief Executive Officer on the terms described in the Offer Letter is subject to his entry into an Employment Agreement with the Company, as well as other standard employment contracts.</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Employment Agreement is expected to include the following additional features, including: (1) severance benefits upon certain qualifying terminations of employment, including termination of Mr. Camardo&#8217;s employment by the Company without &#8220;Cause&#8221; or by Mr. Camardo for &#8220;Good Reason&#8221; (as such terms are defined in the Employment Agreement), consisting of: (a) for a qualifying termination that does not occur within 12 months after a &#8220;Change in Control&#8221; of the Company (as defined in the Employment Agreement), certain accrued obligations, plus 18 months of salary continuation and 18 months of COBRA premiums; and (b) for a qualifying termination that occurs within 12 months after a Change in Control, certain accrued obligations, 24 months of salary continuation, two times Mr. Camardo&#8217;s target annual cash incentive opportunity for the year of termination, a pro-rata payment under the Annual Incentive Program for the year of termination based on actual achievement, and 24 months of COBRA premiums; (2) a requirement that Mr. Camardo execute a customary release of claims in favor of the Company to receive severance compensation; and (3) customary restrictive covenants, including non-competition and confidentiality provisions.</span></div><div style="margin-top:5pt"><span><br/></span></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:27pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date: January 21, 2022 </span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:57.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ATHERSYS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Ivor Macleod</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name: Ivor Macleod<br/>Title: &#160;&#160;Chief Financial Officer</span></td></tr></table></div><div style="height:27pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "athx-20220114.htm", "description": "8-K", "secsgml_size_bytes": 44984}]
{"company-data": {"conformed-name": "ATHERSYS, INC / NEW", "cik": "0001368148", "assigned-sic": "2834", "irs-number": "204864095", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-33876", "film-number": "22543423"}, "business-address": {"street1": "3201 CARNEGIE AVENUE", "city": "CLEVELAND", "state": "OH", "zip": "44115-2634", "phone": "216-431-9900"}, "mail-address": {"street1": "3201 CARNEGIE AVENUE", "city": "CLEVELAND", "state": "OH", "zip": "44115-2634"}, "former-company": {"former-conformed-name": "BTHC VI Inc", "date-changed": "20060629"}}
athx-20220114
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
January 14, 2022
Athersys, Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware
001-33876
20-4864095
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
3201 Carnegie Avenue,
Cleveland,
Ohio
44115-2634
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including area code: (
216
)
431-9900
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, par value $0.001 per share
ATHX
The NASDAQ Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 20, 2022, Athersys, Inc. (the "Company", "we", "us", or "our") announced that the Board of Directors of the Company (the "Board") appointed Daniel A. Camardo to the Board and also named Mr. Camardo as the Company's Chief Executive Officer, each effective as of February 14, 2022. William O. Lehmann, the Company's Interim Chief Executive Officer, will continue to serve as the Company's President and Chief Operating Officer.
Mr. Camardo, age 53, currently serves as the President, U.S., and the Executive Vice President of Horizon Therapeutics plc, a global biotechnology company, at the Rare Disease and Inflammation Business Unit and previously served as Group Vice President
from September 2015 to August 2020.
Before joining Horizon Therapeutics, Mr. Camardo was Vice President of Sales and Operations at Clarus Therapeutics, a start-up company focused on men's health, from July 2014 to September 2015. Prior to joining Clarus Therapeutics, Mr. Camardo served from 2003 to 2014 at Astellas Pharma US, an affiliate of Astellas Pharma Inc., a Japanese global pharmaceutical research company, in various roles, including Senior Director, U.S. Commercial Operations and Senior Director, Market Intelligence and Analytics.
In connection with Mr. Camardo's appointment as Chief Executive Officer, we have entered into an offer letter agreement with Mr. Camardo (the "Offer Letter"), the key compensation terms of which are expected to be memorialized in an employment agreement with Mr. Camardo (an "Employment Agreement"). The Offer Letter includes the following material terms:
•
Mr. Camardo's annual base salary rate during the term of his employment will be $600,000, subject to potential increases from time to time at the discretion of the Board or the Compensation Committee of the Board (the "Committee").
•
A cash signing bonus of $250,000, to be paid within 30 days of the date Mr. Camardo commences employment with the Company (the "Commencement Date"). In the event that Mr. Camardo voluntarily terminates his employment within twelve months of the Commencement Date, he will be required to repay the full amount of the signing bonus.
•
As an inducement to Mr. Camardo's acceptance of employment with the Company, the Company has determined to grant to Mr. Camardo an initial equity award that is intended to be an inducement award under Rule 5635(c)(4) of the Nasdaq Stock Market Listing Rules (the "Inducement Award"). The Inducement Award will be a stock option award to purchase 10,000,000 shares of the Company's common stock at a per share exercise price equal to the closing price of a share of the Company's common stock on the grant date. With regard to 4,000,000 shares, vesting of the Inducement Award will generally occur over a four-year period, with 25% of such portion of the award generally vesting on the first anniversary of the grant date and the remainder generally vesting monthly in substantially equal installments over the remaining 36 months. With regard to 6,000,000 shares, vesting of the Inducement Award will generally occur upon achievement of certain Company milestones, including FDA manufacturing process and marketing approvals, cumulative product sales, and business development and fundraising activities, as and when reasonably evaluated and determined by the Board in its sole discretion. The Inducement Award will generally have a 10-year term.
•
Mr. Camardo will be eligible to participate, during his employment, in the Company's annual cash incentive compensation program (the "Annual Incentive Program") on terms substantially similar to those that apply to other executive officers of the Company, with a target annual cash incentive opportunity equal to 60% of Mr. Camardo's annual base salary (and no guaranteed minimum payment), subject to Company performance as designed annually for the Annual Incentive Program by the Board or the Committee.
•
Beginning in 2022, Mr. Camardo will be eligible to participate, during his employment, in the Company's annual stock-based award program on terms substantially similar to those that apply to other executive officers of the Company. The terms of such awards will be determined annually at the discretion of the Board or the Committee.
•
While employed by the Company, Mr. Camardo will be eligible to participate in the Company's employee benefit plans (including certain retirement and health and welfare benefit plans) on terms substantially similar to those that apply for other executive officers of the Company from time to time. Mr. Camardo will also be entitled to 20 days of paid vacation per year of full-time employment with the Company.
•
Mr. Camardo will be entitled to receive certain severance benefits under the terms of the Employment Agreement.
•
The Offer Letter provides that Mr. Camardo's employment as Chief Executive Officer on the terms described in the Offer Letter is subject to his entry into an Employment Agreement with the Company, as well as other standard employment contracts.
The Employment Agreement is expected to include the following additional features, including: (1) severance benefits upon certain qualifying terminations of employment, including termination of Mr. Camardo's employment by the Company without "Cause" or by Mr. Camardo for "Good Reason" (as such terms are defined in the Employment Agreement), consisting of: (a) for a qualifying termination that does not occur within 12 months after a "Change in Control" of the Company (as defined in the Employment Agreement), certain accrued obligations, plus 18 months of salary continuation and 18 months of COBRA premiums; and (b) for a qualifying termination that occurs within 12 months after a Change in Control, certain accrued obligations, 24 months of salary continuation, two times Mr. Camardo's target annual cash incentive opportunity for the year of termination, a pro-rata payment under the Annual Incentive Program for the year of termination based on actual achievement, and 24 months of COBRA premiums; (2) a requirement that Mr. Camardo execute a customary release of claims in favor of the Company to receive severance compensation; and (3) customary restrictive covenants, including non-competition and confidentiality provisions.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 21, 2022
ATHERSYS, INC.
By:
/s/ Ivor Macleod
Name: Ivor Macleod
Title:   Chief Financial Officer